23 related articles for article (PubMed ID: 1909189)
1. Application of a wide-range yeast vector (CoMed) system to recombinant protein production in dimorphic Arxula adeninivorans, methylotrophic Hansenula polymorpha and other yeasts.
Steinborn G; Böer E; Scholz A; Tag K; Kunze G; Gellissen G
Microb Cell Fact; 2006 Nov; 5():33. PubMed ID: 17105649
[TBL] [Abstract][Full Text] [Related]
2. Activation of human monocyte cytotoxicity by natural and recombinant immune interferon.
Le J; Prensky W; Yip YK; Chang Z; Hoffman T; Stevenson HC; Balazs I; Sadlik JR; Vilcek J
J Immunol; 1983 Dec; 131(6):2821-6. PubMed ID: 6417232
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of recombinant human interferon-gamma and interleukin 2 on natural killer cell activity of peripheral blood in early human development.
Ueno Y; Miyawaki T; Seki H; Matsuda A; Taga K; Sato H; Taniguchi N
J Immunol; 1985 Jul; 135(1):180-4. PubMed ID: 3923100
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the purity of recombinant proteins and detection of residual protein contaminants via N-terminal microsequencing and database searching.
Jin DY; Zhang ZQ; Zhou YA; Hou YD
Chin J Biotechnol; 1991; 7(2):105-11. PubMed ID: 1806020
[TBL] [Abstract][Full Text] [Related]
5. Characterisation and quantification of equine interferon gamma.
Gutmann S; Zawatzky R; Müller M
Vet Immunol Immunopathol; 2005 Mar; 104(1-2):105-15. PubMed ID: 15661336
[TBL] [Abstract][Full Text] [Related]
6. Construction, purification and biological activities of recombinant human interleukin-2 analogs.
Boone T; Chazin V; Kenney W; Swanson E; Altrock B
Dev Biol Stand; 1988; 69():157-68. PubMed ID: 3066670
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations.
Thurman GB; Maluish AE; Rossio JL; Schlick E; Onozaki K; Talmadge JE; Procopio AD; Ortaldo JR; Ruscetti FW; Stevenson HC
J Biol Response Mod; 1986 Feb; 5(1):85-107. PubMed ID: 3514800
[TBL] [Abstract][Full Text] [Related]
8. Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation.
Razaghi A; Owens L; Heimann K
J Biotechnol; 2016 Dec; 240():48-60. PubMed ID: 27794496
[TBL] [Abstract][Full Text] [Related]
9. [New development of hydrophobic interaction chromatography and its applications in biochemical research].
Liu T; Geng X
Se Pu; 1998 Jan; 16(1):30-4. PubMed ID: 11324476
[TBL] [Abstract][Full Text] [Related]
10. Development and shelf-life determination of recombinant interleukin-2 (proleukin).
Geigert J; Solli N; Woehleke P; Vemuri S
Pharm Biotechnol; 1993; 5():249-62. PubMed ID: 8019696
[No Abstract] [Full Text] [Related]
11. Characterization of human interferon-gamma and human interleukin-2 from recombinant mammalian cell lines and peripheral blood lymphocytes.
Riske FJ; Cullen BR; Chizzonite R
Lymphokine Cytokine Res; 1991 Jun; 10(3):213-8. PubMed ID: 1909189
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
